Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.

Vaccine
Lianxing LiuYiming Shao

Abstract

To develop an effective HIV vaccine strategy that can induce cross-reactive neutralizing antibody. Codon-optimized gp140 and gp145 env genes derived from HIV-1(cn54), a CRF07 B'/C recombinant strain, were constructed as DNA and recombinant Tiantan vaccinia (rTV) vaccines. The effect of heterologous immunization with gp140 and gp145 was tested in mice and guinea pigs. T cell responses were detected using the IFN-γ ELISPOT assay. A panel of primary isolates of clade B' and B'/C HIV-1 and TZM-bl cells was used to determine the neutralizing activity of immunized sera. The neutralizing antibodies (NAbs) induced by the heterologous immunogen immunization neutralized all HIV-1 B' and B'/C primary isolates in the guinea pig model. Gp145 and gp140 heterologous prime-boost induced the best neutralizing antibody response with a broad neutralizing spectrum and the highest titer of 1:270 at 6 weeks after the last inoculation. However, the T cell response to HIV-1 peptides was significantly weaker than the gp145+gp145 homologous prime-boost. This heterologous prime-boost immunization strategy could be used to design immunogen-generating broad neutralizing antibodies against genetic variance pathogens.

References

Jun 1, 1994·AIDS Research and Human Retroviruses·T J Matthews
May 22, 1997·Nature·J Binley, J P Moore
Jun 12, 1998·Nature Medicine·J N ReitterR C Desrosiers
May 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·T L HoffmanR W Doms
Jun 29, 2002·Science·Brian GaschenBette Korber
Aug 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Timothy FoutsRanajit Pal
Jul 5, 2005·Journal of Virology·Christopher J MillerAshley T Haase
Jun 2, 2007·Proceedings of the National Academy of Sciences of the United States of America·Peng Fei ZhangGerald V Quinnan
Jan 11, 2008·AIDS Research and Human Retroviruses·Lianxing LiuYiming Shao
Jan 29, 2008·Biochimica Et Biophysica Acta·Maier LorizateJosé L Nieva
Mar 14, 2009·Chembiochem : a European Journal of Chemical Biology·Ana S VeigaMarie Isabel Aguilar

❮ Previous
Next ❯

Citations

Apr 8, 2016·Vaccine·Emmanuel Ato WilliamsMaurizio Zazzi
Mar 19, 2014·Human Vaccines & Immunotherapeutics·Jean-Louis ExclerJerome H Kim
Dec 30, 2017·Human Gene Therapy·Qiong LinDe-Pei Liu
Sep 25, 2019·Vaccines·Sarah WilmschenJanine Kimpel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.